About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

The link between hepatic fat and IPFD observed in young individuals with good cardiometabolic health diminished in older ...

Ozempic and other glucagon-like peptide-1 (GPL-1) agonist medications accounted for 10% of the state employee health plan’s ...

A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...